Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2814 dose-finding study with concurrent lecanemab in early Alzheimer's disease
jRCT2031240393Phase 2Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of etalanetug and lecanemab in Alzheimer's disease (AD) (5 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Change from baseline in cerebrospinal fluid microtubule-binding region-tau-243. Started Nov 2024; status: active, not recruiting.
02
Drugs
etalanetuglecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031240393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240393.